Keywords: merck, investment, invested, million, medarex, new, jersey-based
Merck Investment
Article | 05 September 1994
- Merck has invested $3.2 million in Medarex, a New Jersey-based biotechnology firm, in exchange for a 6% equity position (around 450,000 shares). The ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
